CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.
You may also be interested in...
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
A couple of months after licensing the late-stage kidney disease drug sparsentan from Travere, the Swiss group has beefed up its nephrology activities by buying Mallorca-based Sanifit and Swiss outfit Inositec.